Clinical Trial: Idiopathic Pulmonary Fibrosis (IPF)-Related Chronic Cough Reduction With Nalbuphine Extended-Release (NAL ER) Tablets

U.S., June 27 -- ClinicalTrials.gov registry received information related to the study (NCT07671911) titled 'Idiopathic Pulmonary Fibrosis (IPF)-Related Chronic Cough Reduction With Nalbuphine Extended-Release (NAL ER) Tablets' on June 22.

Brief Summary: The primary purpose is to evaluate the safety and efficacy of NAL ER for the treatment of chronic cough in participants with Idiopathic Pulmonary Fibrosis (IPF).

Study Start Date: June, 2026

Study Type: INTERVENTIONAL

Condition: Idiopathic Pulmonary Fibrosis

Intervention: DRUG: NAL ER

Oral tablets

DRUG: Placebo

Oral tablets

Recruitment Status: NOT_YET_RECRUITING

Sponsor: Trevi Therapeutics

Disclaimer: Curated by HT Syndication....